CRP and myocardial infarction: Moreover, anti-inflammatory therapy with canalikumab, a therapeutic monoclonal antibody targeting interleukin-1β, led to a significantly lower incidence of recurrent cardiovascular events than placebo in patients with previous myocardial infarction (MI) and a high-sensitivity C-reactive protein level (2 mg or more per liter) [9].